CagriSema Falls Short vs Zepbound in Head-to-Head Trial
Novo’s new obesity shot CagriSema lost a head-to-head battle with Lilly’s tirzepatide. 23% weight loss is strong but not enough to win this round.
/ 67 items
#LLY↓
Novo Nordisk Sues Hims & Hers Over Weight-Loss Drug Knockoffs
Danish pharma giant Novo Nordisk files patent lawsuit against telehealth company Hims & Hers for selling unauthorized versions of Wegovy and Ozempic weight-loss medications.
Lilly Acquires Orna Therapeutics for Up to $2.4 Billion
Eli Lilly acquires Orna Therapeutics to advance groundbreaking in vivo CAR-T therapies for autoimmune diseases using circular RNA technology.
FDA Cracks Down on Compounded GLP-1 Weight Loss Drugs
FDA plans to restrict non-approved compounded GLP-1 drugs sold by Hims & Hers and compounding pharmacies, citing safety concerns and misleading marketing practices.
FDA Commissioner Warns Against "Illegal Copycat" Weight-Loss Drugs
FDA takes aim at compounded weight-loss drugs like Hims' $49 Wegovy alternative, raising safety concerns over unapproved copycat medications flooding the market.
Hims & Hers Launches $49 Wegovy Alternative, Shaking Up Weight Loss Market
Hims & Hers offers compounded semaglutide pill at $49/month introductory price, significantly undercutting Novo Nordisk's $199 Wegovy brand-name treatment with same active ingredient.